NKGen Biotech, Inc. (NKGN)
| Market Cap | 37.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -82.95M |
| Shares Out | 22.81M |
| EPS (ttm) | -5.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 125,814 |
| Open | 1.590 |
| Previous Close | 1.640 |
| Day's Range | 1.620 - 1.900 |
| 52-Week Range | 0.780 - 6.700 |
| Beta | 0.44 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 16, 2024 |
About NKGN
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California. [Read more]
Financial Performance
Financial StatementsNews
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson's Disease
NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients with Parkinson's disease.
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit
In vitro studies with SNK01 have shown a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also secreting immunoregulatory cytokines and identifying and eliminating a...
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SANTA ANA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercializa...
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit
SANTA ANA, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercializa...
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
The Company's neurodegenerative clinical program remains on track, with continued advancement of the Alzheimer's Phase 2 trial and anticipation of Parkinson's Phase 1/2a trial initiation.
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference
SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer's patients.
NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer's Disease at the Tau2024 Global Conference
SANTA ANA, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercializa...
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's Disease
NKGen Biotech's autologous clinical program product candidate, SNK01, demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer's Disease (“AD”) in its Phase 1 do...
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease
NKGen's SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA clearance by Health Canada for a phase 1/2a clinical trial in moderate Alzheimer's...
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
– SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer's Disease, expect to initiate Phase I/IIa by year end
NKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference
90% of patients demonstrated improvement or maintained stable cognitive function as per Alzheimer's disease composite score (ADCOMS) following 11 weeks
NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer's Disease
NKGen's neurodegenerative program continues to advance with dosing in the Phase 1/2a clinical trial anticipated to commence by year-end 2023
NKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference
SANTA ANA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercializati...
NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023
SANTA ANA, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercializati...
NKGen Announces Poster Presentation at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023
SANTA ANA, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercializati...
NKGen Biotech, Inc. Announces Closing of Business Combination
Company to Commence Trading on Nasdaq under Ticker Symbol “NKGN” on Monday, October 2, 2023 Company to Commence Trading on Nasdaq under Ticker Symbol “NKGN” on Monday, October 2, 2023
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023
THE WOODLANDS, Texas , Sept. 22, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the "Company" or "Graf"), announced today that on September 20, 2023, it adjourned, witho...
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023
THE WOODLANDS, Texas , Sept. 14, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the "Company" or "Graf"), announced today that on September 13, 2023, it adjourned, witho...
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023
THE WOODLANDS, Texas , Sept. 11, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the "Company" or "Graf"), announced today that on September 8, 2023, it adjourned, withou...
Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023
THE WOODLANDS, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR-UN, GFOR-WT) (the “Company” or “Graf”), announced today that it intends to adjourn, without conducti...
NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors
SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovati...
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business Combination
Special Meeting of Graf Stockholders to Approve Proposed Business Combination to be Held on August 30, 2023
NKGen Biotech and Graf Acquisition Corp. IV Announce the Nomination of Two Independent Directors for the Board of Directors of the Post-Business Combination Public Company
SANTA ANA, Calif. and THE WOODLANDS, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and comme...
NKGen Biotech Inc. and Graf Acquisition Corp. IV to Co-Host Investor Event
SANTA ANA, Calif. and THE WOODLANDS, Texas, July 06, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of i...
Graf Acquisition Corp. IV Currently Has Proxies from More Than 65% of its Stockholders to Approve Extension
THE WOODLANDS, Texas--(BUSINESS WIRE)--Graf Acquisition Corp. IV (NYSE: GFOR) (“Graf”), announced today that it has been informed that it currently has received stockholder votes from more than 65% of...